Speaker Profile
M.D., Chairman and CEO, ArsenalBio
Biography
Ken Drazan, MD, is the Chairman, CEO, and Co-Founder of ArsenalBio, a pioneering company in the field of cell therapy and gene editing. Prior to his role at ArsenalBio, Dr. Drazan served as President and Chief Business Officer of GRAIL, a company focused on early cancer detection which was acquired by Illumina. He also founded and was a Board Director at Verb Surgical, which was later acquired by Johnson Johnson. Additionally, Dr. Drazan co-founded Bertram Capital, a private equity firm managing $1.9 billion in assets. He earned his medical degree from Yale University. Throughout his career, Dr. Drazan has been instrumental in advancing technologies that leverage AI and high-performance computing in precision medicine, significantly impacting the fields of gene editing and cell therapy.
Session Abstract – PMWC 2025 Silicon Valley
Track Chair:
Gad Getz, Broad Institute
- PMWC 2025 Luminary Award
Luminary Honoree: Jensen Huang, Nvidia
- Keynote
- Jensen Huang, Nvidia
- AI Horizons in Precision Medicine: Decoding Tomorrow’s Innovations
Chair: TBA
- Ken Drazan, ArsenalBio
- Beyond LLMs: Harnessing Advanced AI Models for Genomics and Transcriptomics (PANEL)
Chair: Gad Getz, Broad Institute
- Yasin Şenbabaoğlu, CZ Biohub San Francisco
- Asaf Zifran, PrismAI - Advancing Global Health through Data Sharing: Practical Strategies and Success Stories (PANEL)
Chair: Peter Goodhand, GA4GH
- Chris Lunt, All of Us
- Karen Miga, UCSC
- Philip Awadalla, Ontario Institute for Cancer Research
- Knowledge Graphs, LLMs & Foundation Models for Enhanced Drug Development
- Janusz Dutkowski, Data4Cure
- Paul Rejto, Pfizer
- Quantum Leap: The Future of AI and Machine Learning with Quantum Computing
Chair: Matthias Troyer, Microsoft
- Yudong Cao, Zapata Computing
